Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Amidate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 7/20 | 0.93 |
| ▸ | GABRB2 known ✓ | P47870 | 6/20 | 0.93 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.93 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amidate SCHEMBL1817757 | 0.96 | GABRA1 (1.00) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL39485 | 0.96 | GABRA1 (1.00) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Etomidate SCHEMBL39487 | 0.96 | GABRA1 (1.00) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| S-Etomidate SCHEMBL39486 | 0.96 | GABRA1 (1.00) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL5960112 | 0.95 | GABRA1 (0.88) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Etomidate SCHEMBL11323863 | 0.95 | GABRA1 (0.97) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL1098161 | 0.95 | GABRA1 (0.97) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL22502728 | 0.95 | GABRA1 (0.97) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL21773562 | 0.95 | GABRA1 (0.97) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 | |
| Amidate SCHEMBL363786 | 0.95 | GABRA1 (0.97) | GABRA1GABRB2CYP11B2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240093204-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-21 | — | — | US | claimed |
| US-20240093203-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | claimed |
| US-11807853-B2 | Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-07 | — | — | US | claimed |
| EP-4237436-A2 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT CANCER | Garcia-Blanco, Mariano A. (US) | 2023-09-06 | — | — | EP | claimed |
| US-11591597-B2 | MicroRNAs as therapeutic targets for ischemic stroke | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-02-28 | — | — | US | claimed |
| WO-2022094320-A2 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT CANCER | GARCIA BLANCO MARIANO A (US) | 2022-05-05 | — | — | WO | claimed |
| US-20210403920-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-12-30 | — | — | US | claimed |
| US-11118186-B2 | Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-14 | — | — | US | claimed |
| US-20210238593-A1 | MICRORNAS AS THERAPEUTIC TARGETS FOR ISCHEMIC STROKE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-08-05 | — | — | US | claimed |
| US-20210024938-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-28 | — | — | US | claimed |
| EP-3768702-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MOLULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | Board of Regents, The University of Texas System (US) | 2021-01-27 | — | — | EP | claimed |
| WO-2019204574-A1 | MICRORNAS AS THERAPEUTIC TARGETS FOR ISCHEMIC STROKE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2019-10-24 | — | — | WO | claimed |
| WO-2019183570-A1 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MOLULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-26 | — | — | WO | claimed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | claimed |
| US-20150267200-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | US | claimed |
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11981896-B2 | p21 mRNA target areas for silencing | 1E THERAPEUTICS LTD. (IL) | 2024-05-14 | — | — | US | disclosed |
| WO-2001059102-A2 | NUCLEOZYMES WITH ENDONUCLEASE ACTIVITY | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001057206-A2 | METHOD AND REAGENT FOR THE INHIBITION OF CHECKPOINT KINASE-1 (CHK 1) ENZYME | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |